-
ZYNE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
Zynerba Pharmaceuticals (ZYNE)
Company Profile
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.97 mm | 35.97 mm | 35.97 mm | 35.97 mm | 35.97 mm | 35.97 mm |
Cash burn (monthly) | 2.81 mm | 2.21 mm | 3.71 mm | 3.23 mm | 2.81 mm | 2.64 mm |
Cash used (since last report) | 50.08 mm | 39.38 mm | 66.14 mm | 57.59 mm | 49.99 mm | 46.98 mm |
Cash remaining | -14.11 mm | -3.41 mm | -30.17 mm | -21.62 mm | -14.02 mm | -11.01 mm |
Runway (months of cash) | -5.0 | -1.5 | -8.1 | -6.7 | -5.0 | -4.2 |
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 19 |
Closed positions | 16 |
Increased positions | 3 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 13.16 bn |
Total shares | 19.10 mm |
Total puts | 18.30 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
HRMY Harmony Biosciences | 7.59 mm | $0.00 |
Beryl Capital Management | 4.90 mm | $6.25 bn |
Highbridge Capital Management | 2.28 mm | $2.91 bn |
Yakira Capital Management | 620.02 k | $790.52 mm |
Renaissance Technologies | 605.70 k | $772.00 k |
CSS | 476.83 k | $607.96 mm |
Deltec Asset Management | 475.00 k | $605.63 mm |
Millennium Management | 325.24 k | $413.05 mm |
Jane Street | 282.48 k | $360.16 mm |
Crystalline Management | 230.82 k | $294.29 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Oct 23 | Terri B Sebree | Common Stock | Dispose U | No | No | 0 | 425,000 | 0.00 | 0 | |
10 Oct 23 | Terri B Sebree | Common Stock | Grant | Acquire A | No | No | 0 | 170,000 | 0.00 | 425,000 |
10 Oct 23 | Terri B Sebree | Common Stock | Dispose U | No | No | 0 | 341,241 | 0.00 | 255,000 | |
10 Oct 23 | Terri B Sebree | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.41 | 125,000 | 301.25 k | 0 |
10 Oct 23 | Albert P Parker | Common Stock | Dispose U | No | No | 0 | 278,333 | 0.00 | 0 | |
10 Oct 23 | Albert P Parker | Common Stock | Grant | Acquire A | No | No | 0 | 85,000 | 0.00 | 278,333 |
10 Oct 23 | Albert P Parker | Common Stock | Dispose U | No | No | 0 | 33,685 | 0.00 | 193,333 | |
10 Oct 23 | Albert P Parker | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.7 | 200,000 | 540.00 k | 0 |
10 Oct 23 | Kenneth T Jones | Common Stock | Dispose U | No | No | 0 | 75,000 | 0.00 | 0 | |
10 Oct 23 | Kenneth T Jones | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 75,000 |